Ytrrium-90 transarterial radioembolization in patients with gastrointestinal malignancies

• D. Viñal ^[1] ; A. Minaya-Bravo ^[2] ; I. Prieto ^[1] ; J. Feliu ^[1] ; N. Rodriguez-Salas ^[1]
  1. [1] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  2. [2] Department of General and Digestive Surgery, Hospital Universitario del Henares, Coslada, 28822, Madrid, Spain Universidad Francisco de Vitoria, Madrid, Spain
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 5 (May), 2022, págs. 796-808
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Transarterial radioembolization (TARE) with yttrium-90 (Y90) is a promising alternative strategy to treat liver tumors and liver metastasis from colorectal cancer (CRC), as it selectively delivers radioactive isotopes to the tumor via the hepatic artery, sparring surrounding liver tissue. The landscape of TARE indications is constantly evolving. This strategy is considered for patients with hepatocellular carcinoma (HCC) with liver-confined disease and preserved liver function in whom neither TACE nor systemic therapy is possible. In patients with liver metastases from CRC, TARE is advised when other chemotherapeutic options have failed. Recent phase III trials have not succeeded to prove benefit in overall survival; however, it has helped to better understand the patients that may benefit from TARE based on subgroup analysis. New strategies and treatment combinations are being investigated in ongoing clinical trials. The aim of this review is to summarize the clinical applications of TARE in patients with gastrointestinal malignancies.